

Brian C-H Chiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1906704/publications.pdf>

Version: 2024-02-01

63
papers

2,259
citations

279487

23
h-index

214527

47
g-index

63
all docs

63
docs citations

63
times ranked

3051
citing authors

#	ARTICLE	IF	CITATIONS
1	The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women. <i>Breast Cancer</i> , 2022, 29, 287-295.	1.3	4
2	Physical functioning, frailty and risks of locally-advanced breast cancer among older women. <i>Breast</i> , 2022, 64, 19-28.	0.9	0
3	Sex differences in outcomes in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 192, e66-e69.	1.2	12
4	Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma. <i>Npj Genomic Medicine</i> , 2021, 6, 11.	1.7	13
5	Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare. <i>JCO Oncology Practice</i> , 2021, 17, e294-e312.	1.4	7
6	Disparities in diagnosis, treatment and survival between Black and White Parkinson patients. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 7-12.	1.1	5
7	Associations between frailty and cancer-specific mortality among older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 769-779.	1.1	10
8	Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e2118410.	2.8	1
9	Development of an Inclusive Risk Prognostic Index for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 3789-3789.	0.6	0
10	Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma. <i>Blood</i> , 2021, 138, 4116-4116.	0.6	3
11	Loss of 5-hydroxymethylcytosine expression is nearuniversal in B-cell lymphomas with variable mutations in epigenetic regulators. <i>Haematologica</i> , 2021, , .	1.7	2
12	Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 23664.	1.6	4
13	Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. <i>Supportive Care in Cancer</i> , 2020, 28, 4097-4106.	1.0	12
14	Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. <i>Blood Cancer Journal</i> , 2020, 10, 80.	2.8	35
15	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020, 16, e1169-e1180.	1.4	8
16	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma. <i>International Journal of Cancer</i> , 2020, 147, 1300-1305.	2.3	6
17	Self-reported health and survival in older patients diagnosed with multiple myeloma. <i>Cancer Causes and Control</i> , 2020, 31, 641-650.	0.8	7
18	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
20	Application of the High-Throughput TAB-Array for the Discovery of Novel 5-Hydroxymethylcytosine Biomarkers in Pancreatic Ductal Adenocarcinoma. <i>Epigenomes</i> , 2019, 3, 16.	0.8	15
21	Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 2195-2205.	6.1	180
22	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. <i>Cancer Causes and Control</i> , 2019, 30, 889-900.	0.8	4
23	Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. <i>Cancer Communications</i> , 2019, 39, 1-9.	3.7	53
24	Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 2790-2799.	2.5	36
25	Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. <i>Medicine (United States)</i> , 2019, 98, e17960.	0.4	3
26	Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. <i>Cancer</i> , 2019, 125, 1143-1154.	2.0	14
27	Treatment of older patients with diffuse large B-cell lymphoma and mild cognitive impairment or dementia. <i>Journal of Geriatric Oncology</i> , 2019, 10, 510-513.	0.5	4
28	Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma. <i>Blood</i> , 2019, 134, 5494-5494.	0.6	0
29	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. <i>Blood</i> , 2019, 134, 4379-4379.	0.6	0
30	Tumor necrosis factor- α inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. <i>International Journal of Cancer</i> , 2018, 143, 1062-1071.	2.3	42
31	TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases. <i>Blood</i> , 2018, 132, 2984-2984.	0.6	3
32	5-Hydroxymethylcytosines of Circulating Cell-Free DNA and Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 2985-2985.	0.6	0
33	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. <i>Blood</i> , 2018, 132, 4693-4693.	0.6	0
34	Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma. <i>Blood</i> , 2018, 132, 1888-1888.	0.6	0
35	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). <i>Blood</i> , 2016, 128, 3250-3250.	0.6	1
36	Race and Socioeconomic Factors Influencing Treatment Disparities and Comparative Effectiveness in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 841-841.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Racial Differences in Long-Term Risk of Venous Thromboembolism Among Older Patients Following Diagnosis and Treatment of Multiple Myeloma. <i>Blood</i> , 2016, 128, 2071-2071.	0.6	0
38	Epidemiology and Etiology of Non-Hodgkin Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 1-25.	0.2	88
39	Long Term Statin Use and Risk of Multiple Myeloma Among 15.5 Million Taiwanese Adults: A Retrospective Cohort Study. <i>Blood</i> , 2015, 126, 4198-4198.	0.6	4
40	Risk of Non-Hodgkin Lymphoma Following Treatment of Inflammatory Conditions with Tumor Necrosis Factor-Alpha Inhibitors. <i>Blood</i> , 2015, 126, 2653-2653.	0.6	0
41	Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma. <i>Blood</i> , 2015, 126, 2954-2954.	0.6	1
42	An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. <i>Leukemia and Lymphoma</i> , 2013, 54, 1677-1683.	0.6	32
43	Dietary nitrate and nitrite intake and risk of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 945-950.	0.6	10
44	Phytanic acid and the risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2013, 34, 170-175.	1.3	25
45	Meat intake and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2012, 23, 1681-1692.	0.8	23
46	Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2011, 22, 1183-1195.	0.8	25
47	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. <i>Blood</i> , 2010, 116, e90-e98.	0.6	200
48	Pesticides, Chromosomal Aberrations, and Non-Hodgkin's Lymphoma. <i>Journal of Agromedicine</i> , 2009, 14, 250-255.	0.9	32
49	Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2008, 122, 2062-2070.	2.3	104
50	Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2008, 19, 859-867.	0.8	24
51	Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. <i>Blood</i> , 2008, 111, 4029-4038.	0.6	508
52	The Challenges of Epidemiologic Research in Non-Hodgkin Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2059.	3.8	14
53	The Utility of t(14;18) in Understanding Risk Factors for Non-Hodgkin Lymphoma. <i>Journal of the National Cancer Institute Monographs</i> , 2008, 2008, 69-73.	0.9	13
54	Cigarette Smoking, Familial Hematopoietic Cancer, Hair Dye Use, and Risk of t(14;18)-defined Subtypes of Non-Hodgkin's Lymphoma. <i>American Journal of Epidemiology</i> , 2007, 165, 652-659.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Obesity and risk of non-Hodgkin lymphoma (United States). <i>Cancer Causes and Control</i> , 2007, 18, 677-685.	0.8	37
56	Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. <i>Blood</i> , 2006, 108, 1363-1369.	0.6	91
57	Body Mass Index, Abnormal Glucose Metabolism, and Mortality from Hematopoietic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2348-2354.	1.1	70
58	Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study. <i>British Journal of Haematology</i> , 2005, 128, 610-615.	1.2	61
59	Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 525-31.	1.1	21
60	An Update of the Epidemiology of Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 161-168.	2.1	152
61	Dietary factors and risk of colon cancer in Shanghai, China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 201-8.	1.1	54
62	Alcohol Consumption, Family History of Hematolymphoproliferative Cancer, and the Risk of Non-Hodgkin's Lymphoma in Men. <i>Annals of Epidemiology</i> , 2002, 12, 309-315.	0.9	42
63	Diet and Risk of Non-Hodgkin Lymphoma in Older Women. <i>JAMA - Journal of the American Medical Association</i> , 1996, 275, 1315.	3.8	102